Rxrx stock forecast.
Throughout the U.S., the weather can be quite unpredictable, even with state-of-the-art radar, sensors and computer modeling technology right at meteorologists’ fingertips. The Old Farmer’s Almanac first provided valuable statistics and dat...
GE stock has seen extremely strong gains of 85% from levels of $65 in early January 2021 to around $120 now, vs. an increase of about 20% for the S&P 500 over …Stock analysis for Recursion Pharmaceuticals Inc (RXRX:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to next year's forecasts.The consensus statutory numbers ...So keep an eye on this one. 2. Ginkgo Bioworks. Ginkgo Bioworks ( DNA -7.19%) also plans to be a collaboration-driven business, but its approach is a bit different. While it uses its machine ...
The Baudax Bio Inc stock price gained 31.73% on the last trading day (Friday, 24th Nov 2023), rising from $0.0646 to $0.0851. During the last trading day the stock fluctuated 41.83% from a day low at $0.0600 to a day high of $0.0851. The price has fallen in 6 of the last 10 days and is down by -54.02% for this period.
3 апр. 2023 г. ... Unity Stock New CEO Prioritizes Investors Over Stock Price. Jose Najarro ... RXRX Stock Recursion Pharmaceuticals top stocks to buy in August.Get the latest Recursion Pharmaceuticals, Inc RXRX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.
(See RXRX stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy , a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analyst.Future criteria checks 0/6. Recursion Pharmaceuticals's revenue and earnings are forecast to decline at 2.9% and 12.8% per annum respectively. EPS is expected to decline by 9% per annum. Return on equity is forecast to be -471.6% in 3 years.Nov 13, 2023 · Future criteria checks 0/6. Recursion Pharmaceuticals's revenue and earnings are forecast to decline at 2.9% and 12.8% per annum respectively. EPS is expected to decline by 9% per annum. Return on equity is forecast to be -471.6% in 3 years. Recursion Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. RXRX updated stock price target summary.
Recursion Pharmaceuticals Inc Cl A (RXRX) $7.05 0.38 (5.70%) 16:00 EST RXRX Stock Quote Delayed 30 Minutes.
Analyst projections state that RXRX is forecast to be at a low of $9.00 and a high of $35.00. In order for the stock price to hit the forecast high, the stock would need to plunge -435.99% from its current level, while the stock would need to crash -37.83% from its current level to reach the projected low.
Find the latest Recursion Pharmaceuticals, Inc. (RXRX) stock quote, history, news and other vital information to help you with your stock trading and investing. What's going on at Recursion Pharmaceuticals (NASDAQ:RXRX)? Read today's RXRX news from trusted media outlets at MarketBeat. Skip to main content. S&P 500 4,594.63 (+0.59%) DOW 36,245.50 (+0.82%) ... Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Ownership SEC Filings …The Baudax Bio Inc stock price gained 31.73% on the last trading day (Friday, 24th Nov 2023), rising from $0.0646 to $0.0851. During the last trading day the stock fluctuated 41.83% from a day low at $0.0600 to a day high of $0.0851. The price has fallen in 6 of the last 10 days and is down by -54.02% for this period.Nov 29, 2023 · Should You Buy or Sell Recursion Pharmaceuticals Stock? Get The Latest RXRX Stock Analysis, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat. Get the latest Recursion Pharmaceuticals, Inc RXRX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.
Current. -$0.35. 1 Month Ago. -$0.35. 3 Months Ago. -$0.32. Recursion Pharmaceuticals Inc. analyst estimates, including RXRX earnings per share estimates and analyst recommendations.Recursion Pharmaceuticals uses AI and experimental biology to discover new treatments for diseases. Check out why I'm bullish on RXRX stock.The company raised guidance for annual organic revenue growth from an earlier forecast of between 5% and 7% to between 6% and 8%. It also raised annual adjusted EPS to be between $3.70 and $3.85 ...Future criteria checks 0/6. Recursion Pharmaceuticals's revenue and earnings are forecast to decline at 2.9% and 12.8% per annum respectively. EPS is expected to decline by 9% per annum. Return on equity is forecast to be -471.6% in 3 years.Get the latest Recursion Pharmaceuticals Inc (RXRX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.4.31%. €8.59M. RXRX | Complete Recursion Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
For their last quarter, Recursion Pharmaceuticals (RXRX) reported earnings of -$0.43 per share, missing the Zacks Consensus Estimate of -$0.38 per share. This reflects a negative earnings surprise ...
Stock Price Forecast. The 7 analysts offering 12-month price forecasts for Recursion Pharmaceuticals Inc have a median target of 14.00, with a high estimate of 35.00 and a low estimate of 9.00 ...Currently, Wall Street analysts expect the stock to reach $16.00 within the next 12 months. Recursion Pharmaceuticals Inc [NASDAQ: RXRX] shares were valued at $6.11 at the most recent close of the market. An investor can expect a potential return of 161.87% based on the average RXRX price forecast.Get the latest Recursion Pharmaceuticals Inc (RXRX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Discover historical prices for RXRX stock on Yahoo Finance. View daily, weekly or monthly format back to when Recursion Pharmaceuticals, Inc. stock was issued.Taken together with their deep financial resources, Eli Lilly is one of the best positioned companies to take advantage of the AI-biotech trend. Because Eli Lilly’s future is built off a very ...Meta Platforms ( META ): META’s revenues climbed 23% to $34.15 billion in its most recent quarter. Teradyne ( TER ): Resilient Teradyne outshone in the third quarter with an 80-cent Non-GAAP EPS ...Find the latest GoodRx Holdings, Inc. (GDRX) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Performance Outlook. Short Term. 2W - 6W ...
RXRX has a market cap of $1.73bn and a cash balance of $454mn. Research and development expenses were $40.8 million for the third quarter of 2022, while general and administrative expenses were ...
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.34 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.33 per share a year ago.
What this means: Recursion Pharmaceuticals Inc Cl (RXRX) gets an Overall Rank of 60, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value.Recursion Pharmaceuticals Stock Chart and Share Price Forecast, Short-Term "RXRX" Stock Prediction for Next Days and Weeks Walletinvestor.com Recursion Pharmaceuticals Inc (RXRX) Forecast Chart, Long-Term Predictions for Next Months and Year: 2023, 2024 All 39 ARKG ETF Holdings. The portfolio of Cathie Wood updated daily. These are the positions, trades, and weight of all companies in her ARKG Genomic Revolution ETF. Search tickers or categories... Trader's Guide 2024 Ships December 21st.Recursion Pharmaceuticals (RXRX) stock price prediction is 10.137756245264 USD. The Recursion Pharmaceuticals stock forecast is 10.137756245264 USD for 2024 December 02, Monday; and 517.401 USD for 2028 December 02, Saturday with technical analysis. See Recursion Pharmaceuticals, Inc. (RXRX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Find the latest Cerus Corporation (CERS) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Performance Outlook. Short Term. 2W - 6W. Mid ...The 7 analysts offering 1 year price forecasts for RXRX have a max estimate of — and a min estimate of —. Analyst rating Based on 7 analysts giving stock ratings to RXRX in the past 3 months.At the close of trading, the stock’s price was $5.09, to imply a decrease of -3.60% or -$0.19 in intraday trading. The RXRX share’s 52-week high remains $16.75, putting it -229.08% down since that peak but still an impressive 10.81% since price per share fell to its 52-week low of $4.54.JPMorgan Trims Price Target on Recursion Pharmaceuticals to $10 From $11, Maintains Neutral Rating. Nov. 13. MT. Needham Adjusts Recursion Pharmaceuticals Price Target to $15 From $17, Maintains Buy Rating. Nov. 10. MT. Recursion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September …Recursion Pharmaceuticals Stock Chart and Share Price Forecast, Short-Term "RXRX" Stock Prediction for Next Days and Weeks Walletinvestor.com Recursion Pharmaceuticals Inc (RXRX) Forecast Chart, Long-Term Predictions for Next Months and Year: 2023, 2024
60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share.Nov 29, 2023 · Should You Buy or Sell Recursion Pharmaceuticals Stock? Get The Latest RXRX Stock Analysis, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat. Recursion Pharmaceuticals (RXRX 7.88%) is a biotech that's riding a hype wave unlike any other. By staking its fame and investors' cash on its artificial intelligence (AI) platform for drug ...Stock Price Forecast. According to 6 stock analysts, the average 12-month stock price forecast for RXRX stock stock is $15.33, which predicts an …Instagram:https://instagram. saks neimanatmubrokers that accept us clientsreit brokers For RXRX stock, which has suffered sharp losses against a long-term framework, AI may put the underlying company on the right track again. Still, investors need to be aware of separating the ...12 июл. 2023 г. ... RXRX+0.01 (+0.14%) After ... Chris Gibson, Recursion CEO, joins 'Closing Bell Overtime' to talk the company's stock pop after announcing an A.I. ... lowes russellalsym energy stock All 39 ARKG ETF Holdings. The portfolio of Cathie Wood updated daily. These are the positions, trades, and weight of all companies in her ARKG Genomic Revolution ETF. Search tickers or categories... Trader's Guide 2024 Ships December 21st.According to 9 stock analysts, the average 12-month stock price forecast for HP Inc. stock is $31.56, which predicts an increase of 8.57%. The lowest target is $23 and the highest is $39. On average, analysts rate HP Inc. stock as a buy. dow jones tofay Recursion's stock soared 80% following the announcement. Shares of Nvidia, which have helped fuel stock market gains this year amid hopes about its AI computing chips , rose more than 2%."Over the next 10 years, AI could increase productivity by 1.5% per year. And that could increase S&P500 profits by 30% or more over the next decade," Goldman Sach's senior strategist Ben Snider ...